Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Ruxolitinib

2

XVII.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

1
Last update : 17/03/2014
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Ruxolitinib dicontinuation/withdrawal
1

Publications

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib.
Case reports in hematology 2016;2016;2389038 2016
Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis.
Leukemia & lymphoma 2015 May;56;1528-9 2015 May
Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge.
Annals of hematology 2015 Mar;94;519-20 2015 Mar
Ruxolitinib Associated Tuberculosis Presenting as a Neck Lump.
Case reports in infectious diseases 2015;2015;284168 2015
Disseminated tuberculosis associated with ruxolitinib.
Leukemia 2014 Aug;28;1750-1 2014 Aug
Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report.
BMC research notes 2012 Oct 05;5;552 2012 Oct 05

Powered by

  • ^
  • Contact
  • Cookies
  • About